DATATOP: A decade of neuroprotective inquiry

@article{Shoulson1998DATATOPAD,
  title={DATATOP: A decade of neuroprotective inquiry},
  author={I. Shoulson},
  journal={Annals of Neurology},
  year={1998},
  volume={44}
}
In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a… Expand
Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
TLDR
Levodopa‐treated Parkinson's disease patients who had been treated with deprenyl for up to 7 years, compared with patients who were changed to a placebo after about 5 years, experienced slower motor decline and were more likely to develop dyskinesias but less likely to developed freezing of gait. Expand
Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough
TLDR
The need for neuroprotective therapies in PD is explained, results and limitations of previous clinical trials are discussed, and some food for thought is provided for the future research of neuroprotection in PD. Expand
A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
TLDR
Although f -tocopherol did not appear to affect the survival and motor function in ALS, patients receiving riluzole plus f -ocopherol remained longer in the milder states of the ALS Health State scale and showed changes in biochemical markers of oxidative stress. Expand
The Fabulous Neuroprotection of Selegiline: Memoir and Prospectus
  • W. Landau
  • Psychology, Medicine
  • Journal of child neurology
  • 2010
TLDR
The thrust of my critique was not that protective function was disproved, but rather that it was not proved; the unexpected discovery from consistent clinical evaluations that deprenyl directly improved the symptoms of parkinsonism. Expand
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study
TLDR
Neither the primary nor the secondary outcome measures could determine whether a megadose of vitamin E is efficacious in slowing disease progression in ALS as an add-on therapy to riluzol. Expand
Neuroprotection in Parkinson's disease.
  • A. Schapira
  • Medicine, Biology
  • Parkinsonism & related disorders
  • 2009
TLDR
A major focus in Parkinson's disease research is to produce drugs or other interventions that can slow or stop clinical progression and so target dopaminergic and non-dopaminergic pathways, and it is logical to assume that the best chance of developing such therapies will be based on forming a better understanding of the aetiology and pathogenesis of PD. Expand
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin‐induced nigrostriatal dopaminergic degeneration
TLDR
Compared with selegiline, rasagiline is more potent in protecting neurodegeneration induced by UPS impairment and may, therefore, exert disease‐modifying effects in PD. Expand
Targeting the Prodromal Stage of Alzheimer’s Disease: Bioenergetic and Mitochondrial Opportunities
TLDR
The importance of early therapeutic intervention during the prodromal stage that precedes irreversible degeneration in AD is discussed, and a systems biology approach that targets the bioenergetic system rather than a single component of this system is focused on. Expand
Design of clinical trials of gene therapy in Parkinson disease
TLDR
It is concluded that the most feasible designs are for those treatments that are expected to produce a rapid improvement in directly observable symptoms and trials of agents which are likely to produce only a slowing of progression and not a reversal of the disease course. Expand
The Use of Estrogens and Related Compounds in the Treatment of Damage from Cerebral Ischemia
TLDR
Estrogens could prove to be useful therapies in preventing brain damage from strokes using a formulation of E2 that rapidly delivers the steroid, a necessary condition for acute therapy of an ongoing stroke. Expand
...
1
2
3
4
5
...